Terminally ill patient is 'cured' of immune illness after AI identifies drug for 'repurposing'
The patient has iMCD, which has a poor survival rate and few treatment options but an AI tool searched through 4,000 ...
AI predicts effective treatment for rare disease using existing medications
After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD).
3 Generic Drug Stocks to Watch
The main focus in Teva’s innovative portfolio continues to be neuroscience and immunology, with clinical trials for three key assets underway: olanzapine for treatment of schizophrenia, ...
AZoAI on MSN8h
AI Predicts Life-Saving Drug for Rare Disease, Patient Enters Remission
Researchers used an AI-driven approach to identify adalimumab as a potential life-saving treatment for idiopathic ...
manilatimes17h
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...
Amgen Reports Fourth Quarter And Full Year 2024 Financial Results
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...
centerforbiosimilars10h
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...